Elsevier

The Lancet

Volume 342, Issue 8865, 24 July 1993, Pages 203-205
The Lancet

Articles
Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine

https://doi.org/10.1016/0140-6736(93)92298-8Get rights and content

Abstract

From May, 1990, a new schedule of immunisation against diphtheria, tetanus, and pertussis (at 2, 3, and 4 months) replaced the previous more widely spaced schedule. A report that children had lower concentrations of diphtheria and tetanus antibodies a month after an accelerated schedule led us to undertake a controlled study to assess antibody response and the persistence of antibodies a year after immunisation in children receiving vaccine according to widely spaced and accelerated schedules. Concentrations of antibodies to diphtheria and tetanus toxoids and to Bordetella pertussis filamentous haemagglutinin (FHA) were measured by solid-phase radioimmunoassay (SP-RIA). We studied 57 children who received accelerated immunisation at median ages of 11, 16, and 21 weeks and two control cohorts (total n=82) who received vaccine at median ages of 15, 21, and 45 weeks. 6-8 weeks after the third dose the accelerated-schedule group had lower (p<0·0001) geometric mean concentrations of antibody to tetanus (0·522 [95% Cl 0·383-0·710] vs 3·43 [2·45-4·81] IU/mL), diphtheria (0 266 [0 179-0 396] vs 2·39 [0·616-3·53] IU/mL), and FHA (0 044 [0 030-0·063] vs 0·270 [0 196-0·374] units/mL) than the longer-schedule group. 12 months after the third dose the differences between the groups had narrowed (tetanus 0·197 vs 0·341 IU/mL, p=0·29; diphtheria 0·100 vs 0·131 IU/mL, p=0·64; FHA 0 014 vs 0·016 units/mL, p=0·72). At that time all children had tetanus antibody concentrations above protective levels (0·01 IU/mL); only 2 of 31 in the accelerated-schedule group and 3 of 31 in the longer-schedule group had diphtheria antibody concentrations below the protective level. The use of an accelerated schedule of diphtheria, tetanus, and pertussis vaccination is unlikely to lead to an increase in the proportion of children unprotected against these diseases before the preschool booster.

References (16)

There are more references available in the full text version of this article.

Cited by (27)

  • Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom

    2021, EBioMedicine
    Citation Excerpt :

    Notification rates are dependant on the use of diagnostics, reporting and ascertainment per country and therefore do not reflect the real incidence numbers. In response to continued pertussis disease, many countries have adopted an accelerated schedule of primary series vaccinations and all western countries have implemented booster vaccinations in childhood [27,28]. In addition, some countries introduced extra aP boosters for adolescents and adult target populations, including pregnant women, military conscripts, healthcare workers, and older adults [29–34].

  • Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series

    2020, Vaccine
    Citation Excerpt :

    This observation confirms the greater immunogenicity of prime-boost conjugate schedules using the same protein at both phases [19,21]—in this case, tetanus toxoid. The safety data summarized in this report are concordant with rates of local and systemic reactions previously reported for acellular pertussis-containing vaccines and conjugate vaccines given according to this accelerated schedule [22–24]. Finally, the results of this study should be taken in the context of evolving understanding of the mechanisms of effectiveness of conjugate vaccines in general and meningococcal vaccines, in particular.

  • Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial

    2017, Vaccine
    Citation Excerpt :

    Serum values were expressed in µg/ml as the reference serum was calibrated against the international reference serum lot 89S (FDA) [25]. To detect a difference of 10% in antibody levels, 300 infants (150 from each group) needed to be included (α: 0.05, β: 0.10)[26]. Before unblinding, a statistical analysis plan was deposit with the Danish Calmette Study Data Safety and Monitoring Bard.

  • Diphtheria Toxoid

    2017, Plotkin's Vaccines
  • Tetanus Toxoid

    2017, Plotkin's Vaccines
  • Diphtheria toxoid

    2012, Vaccines: Sixth Edition
View all citing articles on Scopus
View full text